Target intelligence / Profile preview

Solute carrier family 25 member 25 (SLC25A25)

Target
SLC25A25
Molecular classification
Transporter, Mitochondrial carrier, Solute carrier family
01

Overview

Solute carrier family 25 member 25 (SLC25A25) is a mitochondrial transporter protein localized to the inner mitochondrial membrane. It functions predominantly as an antiporter for adenyl nucleotides, mediating the exchange of ATP-Mg and inorganic phosphate (Pi) and thereby regulating the mitochondrial pool of adenine nucleotides according to cellular energetic demands. SLC25A25 is a member of the mitochondrial carrier family (SLC25), which is the largest solute transporter family in humans. It plays a critical role in cellular energy homeostasis, with activity modulated by calcium binding. Dysfunction or mutation in SLC25A25 is associated with human diseases such as nephrolithiasis and combined oxidative phosphorylation deficiency, highlighting its importance in mitochondrial physiology and pathology[1][2][3][5][6].

Other names
Mitochondrial adenyl nucleotide antiporter SLC25A25APC3KIAA1896MCSC3SCAMC2UNQ549/PRO1106SCaMC-2PCSCLMCSCMitochondrial ATP-Mg/Pi carrier protein 3Mitochondrial Ca(2+)-dependent solute carrier protein 3Short calcium-binding mitochondrial carrier protein 2Small calcium-binding mitochondrial carrier 2Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 25
02

Mechanism of action

Not applicable/unknown for drugs due to the absence of directly targeting compounds; mechanistically, SLC25A25 operates as an ATP-Mg/Pi antiporter in mitochondria, supporting nucleotide exchange essential for cellular energy management[1][2][3][5].

03

Biological functions

Mitochondrial transport/exchange of adenine nucleotides (e.g., ATP, ADP)Calcium-regulated energy metabolismRegulation of mitochondrial adenyl nucleotide poolsCellular energetic homeostasis
04

Disease associations

NephrolithiasisCombined oxidative phosphorylation deficiencyPotential roles in mitochondrial diseases and cellular energetic pathologies
05

Safety considerations

Potential for mitochondrial dysfunction and impaired energy metabolism; role in rare mitochondrial and metabolic disorders, but no specific safety concerns with direct targeting due to lack of drugs

Beyond the preview

Go deeper on Solute carrier family 25 member 25 (SLC25A25).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 25 member 25 (SLC25A25).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call